Moderna (MRNA) Operating Margin (2017 - 2025)
Moderna (MRNA) has disclosed Operating Margin for 9 consecutive years, with 126.4% as the latest value for Q4 2025.
- On a quarterly basis, Operating Margin fell 1972.0% to 126.4% in Q4 2025 year-over-year; TTM through Dec 2025 was 158.13%, a 4117.0% decrease, with the full-year FY2025 number at 158.13%, down 3622.0% from a year prior.
- Operating Margin was 126.4% for Q4 2025 at Moderna, down from 25.59% in the prior quarter.
- In the past five years, Operating Margin ranged from a high of 75.02% in Q4 2021 to a low of 972.22% in Q1 2025.
- A 5-year average of 180.43% and a median of 11.71% in 2024 define the central range for Operating Margin.
- Peak YoY movement for Operating Margin: surged 170286bps in 2021, then plummeted -73843bps in 2024.
- Moderna's Operating Margin stood at 75.02% in 2021, then tumbled by -59bps to 31.08% in 2022, then tumbled by -99bps to 0.21% in 2023, then tumbled by -50079bps to 106.68% in 2024, then dropped by -18bps to 126.4% in 2025.
- Per Business Quant, the three most recent readings for MRNA's Operating Margin are 126.4% (Q4 2025), 25.59% (Q3 2025), and 638.73% (Q2 2025).